For 15 years, AVAC has published an annual review of biomedical prevention research. Over this period, the focus of the AVAC Report has expanded from AIDS vaccine research alone to the full spectrum of options, including pre-exposure prophylaxis, microbicides, male circumcision and HSV-2 treatment. This comprehensive document reviews progress, makes recommendations and analyzes emerging issues.
Achieving the End—One Year and
AVAC's Report 2012 sets a clock on the global drive to end the AIDS epidemic. The past twelve months have seen remarkable global consensus that it is possible to begin to end the epidemic. The same time period has seen concepts like “combination prevention” and “treatment as prevention” capture the world’s attention. But without specific interim goals—and far more precision about what combination prevention and other key concepts mean—the lofty goal of ending the epidemic will not be achieved.
AVAC Report 2011: The End? lays out a three-part, science-based agenda for ending the AIDS epidemic in our lifetimes. It synthesizes the actions need across the spectrum of existing, emerging and long-term biomedical HIV prevention tools that could change the AIDS response forever. This year's Report also introduces the AVAC "Playbook" which is a new strategic document identifying global and organizational priorities for the next twelve months.
AVAC Report: Turning the Page
We called the 2010 Report Turning the Page because the biomedical prevention field has entered the next chapter of its development. The past year brought the first evidence, from the Thai Prime-Boost trial, that an AIDS vaccine could prevent HIV in humans, as well as significant preclinical findings around potent, HIV-specific neutralizing antibodies. At the same time, two microbicide trials testing the candidate PRO 2000 yielded seemingly different, but ultimately disappointing results, and the field now prepares for the release of results from CAPRISA 004, the first ARV-based microbicide effectiveness trial.
AVAC Report: Piecing Together the
HIV Prevention Puzzle
When conceptualizing this year's Report, we took inspiration from a quotation in the 2006-2008 review of the Bill & Melinda Gates Foundation - funded Collaboration for AIDS Vaccine Discovery, which states that the ultimate goal "is to develop a vaccine that prevents HIV infection or disease, anything less than that can be characterized as progress, but not success."
In the first section of the Report, "Puzzling Out Progress," we report on the AIDS vaccine field, where there's an energized focus on discovery, innovation, and basic science. In the second section, "Puzzling Out Success," we turn to the implications of PrEP and other strategies in efficacy trials today. Throughout, we argue that success will depend on combination approaches: on research plus implementation; on vaccines plus PrEP, should either show benefit; and on communities plus researchers working towards common goals.
AVAC Report 2008: The Search Must Continue
The 2008 AVAC
Report, The Search Must Continue,
provides a comprehensive review of recent
developments in AIDS vaccine research. It
explores the issues that have been raised in
the wake of the failure of Merck's vaccine
candidate and provides context for the events
and major changes of the last year in HIV
AVAC Report 2007: Resetting the Clock
The three sections
of this report outline some specific deadlines
and challenges in AIDS vaccine scientific
strategy, clinical trials, and the broader
realm of HIV prevention. These arenas mesh like
watch gears, and must function just as smoothly
if the field is to proceed.
AVAC Report 2006: AIDS Vaccines: The Next Frontiers
In this report, AVAC
offers its first contribution to the scenario
planning that we think is critical to the
success of the field. The next several years
bring a variety of scenarios which we cannot
encounter unprepared. Instead, the AIDS vaccine
field, and the field of prevention research in
general, must engage in rigorous debate,
dialogue and scenario planning which
anticipates the issues that the next few years
will bring, and ensures that the wide range of
stakeholders are informed and empowered to make
decisions to compete against the virus. In this
report, we present four thought-provoking
chapters, each of which begins with a future
scenario that considers how the world might
look in five or six or ten years'
Report 2005: AIDS Vaccines at the
In this report, we offer recommendations for the field in general, the Global HIV Vaccine Enterprise, policy makers, researchers and communities. Some of these recommendations will be familiar because we've made them before, and we reiterate them because we believe they are still needed. (See our timeline of 10 years of AVAC recommendations for a perspective on progress over the past decade.) We also provide an update on tenofovir pre-exposure prophylaxis research.
AVAC Report 2004: AIDS Vaccine Trials: Getting the Global House in Order
The report focuses on how the field is readying itself for the road ahead. Several chapters address different aspects of "readiness" - a term that means different things to different people, but that is at the heart of the AIDS vaccine advocacy agenda today.
Report 2003: 4 Years and Counting:
How do you Fight a Disease of Mass
When America became frightened by the bio-terror threat, Congress and the Administration moved swiftly to put funding and incentives in place. That same kind of decisive action is needed to accelerate research and ensure an AIDS vaccine is available to all who need it. This report looks at the bioterror model, and provides the results of our new industry survey.
AVAC Report 2002: 5 Years and Counting: Science, Urgency and Courage
Five years away from
the date former President Bill Clinton set as a
goal for finding an AIDS vaccine, there are
more candidate vaccine products in development
than ever before. No one knows if any of the
current experimental vaccines will work. No one
even knows what immune response a vaccine needs
to elicit to prevent HIV disease. The only way
to obtain answers is to ask tens of thousands
of altruistic and courageous participants to
participate in dozens of trials. The only way
to obtain answers is to invest hundreds of
millions of dollars to fund these
AVAC Report 2001: 6 Years and Counting: Can a Shifting Landscape Accelerate an AIDS Vaccine?
In 1996, AVAC was the first organization to demand that development of an AIDS vaccine become a national goal. President Clinton set that goal in May 1997, calling for a successful vaccine by 2007. We are now six years away from the goal and counting. None of the challenges are insurmountable. The optimism that characterizes HIV vaccine research today should drive policy makers and researchers to grapple effectively with the issues that remain. An HIV vaccine is possible. The question is how soon we find it, and who gets it when we do.
AVAC Report 2000: 7 Years and Counting: How Can We Overcome Obstacles to an AIDS Vaccine?
The last year was
one of great activity across US agencies and
throughout the world. This report documents the
steadily increasing activity in the quest for a
vaccine against HIV. We have also identified
several actions necessary to accelerate
development of HIV vaccines, and we outline all
of this in the AVAC report for 2000.
AVAC Report 1999: 8 Years and Counting: What Will Speed the Development of an AIDS Vaccine?
We urge government,
industry, and community to dedicate themselves
to the development of a safe and effective HIV
vaccine. If the goal for 2007 cannot be
achieved, then we need to know what will be
accomplished over the next eight years toward a
vaccine that could bring the HIV pandemic under
control. With 16,000 new HIV infections each
day, the world can afford no delay. This report
describes what each of these sectors has
accomplished during the past year and outlines
what each can do to speed the search for a
AVAC Report 1998: 9 Years and Counting: Will We Have an HIV Vaccine by 2007?
This report surveys
the public- and private-sector efforts on HIV
vaccine research and development in the past
year, with a focus on the US government
agencies and pharmaceutical companies that are
most likely to make a difference. It finds
that, despite an impressive array of dedicated
researchers and increasing funding for HIV
vaccines, the world will fall short of
President Clinton's deadline. US government
research efforts are not focused on results,
leaders err on the side of caution rather than
on moving forward, responsibility is diffuse,
and the nation has stood silent as
pharmaceutical companies, including the world's
largest vaccine producer, make little or no
investment in one of the greatest public health
challenges of our century. AVAC addresses these
obstacles and recommends an agenda for action
in this report.